{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:21:03Z","timestamp":1762507263808,"version":"3.41.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T00:00:00Z","timestamp":1513814400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T00:00:00Z","timestamp":1513814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA03546"],"award-info":[{"award-number":["R01DA03546"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005317","name":"Abell Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006640","name":"Open Society Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006640","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s00213-017-4814-3","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T14:23:46Z","timestamp":1513866226000},"page":"971-981","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Characterizing the subjective, observer-rated, and physiological effects of hydromorphone relative to heroin in a human laboratory study"],"prefix":"10.1007","volume":"235","author":[{"given":"Kelly E.","family":"Dunn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruna","family":"Brands","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George E.","family":"Bigelow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,21]]},"reference":[{"issue":"1","key":"4814_CR1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-3565(25)20047-7","volume":"247","author":"WK Bickel","year":"1988","unstructured":"Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE (1988a) Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther 247(1):47\u201353","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"4814_CR2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0022-3565(25)24264-1","volume":"244","author":"WK Bickel","year":"1988","unstructured":"Bickel WK, Stitzer ML, Liebson IA, Bigelow GE (1988b) Acute physical dependence in man: effects of naloxone after brief morphine exposure. J Pharmacol Exp Ther 244(1):126\u2013132","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"4814_CR3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1526-4637.2011.01075.x","volume":"12","author":"HG Birnbaum","year":"2011","unstructured":"Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL (2011) Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med 12(4):657\u2013667. https:\/\/doi.org\/10.1111\/j.1526-4637.2011.01075.x; 10.1111\/j.1526-4637.2011.01075.x.","journal-title":"Pain Med"},{"issue":"1-3","key":"4814_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.drugalcdep.2011.06.025","volume":"120","author":"P Blanken","year":"2012","unstructured":"Blanken P, Hendriks VM, Koeter MW, van Ree JM, van den Brink W (2012) Craving and illicit heroin use among patients in heroin-assisted treatment. Drug Alcohol Depend 120(1-3):74\u201380. https:\/\/doi.org\/10.1016\/j.drugalcdep.2011.06.025 [doi].","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"4814_CR5","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/j.1360-0443.2012.03803.x","volume":"107","author":"J Bruneau","year":"2012","unstructured":"Bruneau J, Roy E, Arruda N, Zang G, Jutras-Aswad D (2012) The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction 107(7):1318\u20131327. https:\/\/doi.org\/10.1111\/j.1360-0443.2012.03803.x; 10.1111\/j.1360-0443.2012.03803.x.","journal-title":"Addiction"},{"issue":"2","key":"4814_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1037\/1064-1297.14.2.109","volume":"14","author":"CP Carroll","year":"2006","unstructured":"Carroll CP, Walsh SL, Bigelow GE, Strain EC, Preston KL (2006) Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans. Exp Clin Psychopharmacol 14(2):109\u2013120. https:\/\/doi.org\/10.1037\/1064-1297.14.2.109","journal-title":"Exp Clin Psychopharmacol"},{"issue":"Suppl 1","key":"4814_CR7","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.drugalcdep.2009.04.003","volume":"105","author":"LP Carter","year":"2009","unstructured":"Carter LP, Griffiths RR (2009) Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend 105(Suppl 1):S14\u2013S25. https:\/\/doi.org\/10.1016\/j.drugalcdep.2009.04.003.","journal-title":"Drug Alcohol Depend"},{"key":"4814_CR8","first-page":"537","volume":"62","author":"Centers for Disease Control and Prevention (CDC)","year":"2013","unstructured":"Centers for Disease Control and Prevention (CDC) (2013) Vital signs: overdoses of prescription opioid pain relievers and other drugs among women\u2014United States, 1999-2010. MMWR Morb Mortal Wkly Rep 62:537\u2013542","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"22","key":"4814_CR9","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/0024-3205(91)90150-A","volume":"48","author":"ZR Chen","year":"1991","unstructured":"Chen ZR, Irvine RJ, Somogyi AA, Bochner F (1991) Mu receptor binding of some commonly used opioids and their metabolites. Life Sci 48(22):2165\u20132171. https:\/\/doi.org\/10.1016\/0024-3205(91)90150-A","journal-title":"Life Sci"},{"issue":"4","key":"4814_CR10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0885-3924(00)00191-3","volume":"20","author":"P Compton","year":"2000","unstructured":"Compton P, Charuvastra VC, Kintaudi K, Ling W (2000) Pain responses in methadone-maintained opioid abusers. J Pain Symptom Manag 20(4):237\u2013245. https:\/\/doi.org\/10.1016\/S0885-3924(00)00191-3","journal-title":"J Pain Symptom Manag"},{"issue":"9","key":"4814_CR11","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jpain.2003.08.003","volume":"4","author":"P Compton","year":"2003","unstructured":"Compton P, Athanasos P, Elashoff D (2003) Withdrawal hyperalgesia after acute opioid physical dependence in nonaddicted humans: a preliminary study. J Pain 4(9):511\u2013519. https:\/\/doi.org\/10.1016\/j.jpain.2003.08.003","journal-title":"J Pain"},{"issue":"2","key":"4814_CR12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMra1508490","volume":"374","author":"WM Compton","year":"2016","unstructured":"Compton WM, Jones CM, Baldwin GT (2016) Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med 374(2):154\u2013163. https:\/\/doi.org\/10.1056\/NEJMra1508490","journal-title":"N Engl J Med"},{"issue":"4","key":"4814_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1159\/000369337","volume":"21","author":"I Demaret","year":"2015","unstructured":"Demaret I, Quertemont E, Litran G, Magoga C, Deblire C, Dubois N, De Roubaix J, Charlier C, Lemaitre A, Ansseau M (2015) Efficacy of heroin-assisted treatment in Belgium: a randomised controlled trial. Eur Addict Res 21(4):179\u2013187. https:\/\/doi.org\/10.1159\/000369337","journal-title":"Eur Addict Res"},{"issue":"3","key":"4814_CR14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00213-010-1898-4","volume":"211","author":"AN Duke","year":"2010","unstructured":"Duke AN, Correia CJ, Walsh SL, Bigelow GE, Strain EC (2010) Acute effects of intramuscular and sublingual buprenorphine and buprenorphine\/naloxone in non-dependent opioid abusers. Psychopharmacology 211(3):303\u2013312. https:\/\/doi.org\/10.1007\/s00213-010-1898-4","journal-title":"Psychopharmacology"},{"issue":"1","key":"4814_CR15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1124\/jpet.111.181131","volume":"338","author":"AN Duke","year":"2011","unstructured":"Duke AN, Bigelow GE, Lanier RK, Strain EC (2011) Discriminative stimulus effects of tramadol in humans. J Pharmacol Exp Ther 338(1):255\u2013262. https:\/\/doi.org\/10.1124\/jpet.111.181131","journal-title":"J Pharmacol Exp Ther"},{"key":"4814_CR16","doi-asserted-by":"publisher","unstructured":"Ferri M, Davoli M, Perucci CA (2011) Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev (12):CD003410. https:\/\/doi.org\/10.1002\/14651858.CD003410.pub4","DOI":"10.1002\/14651858.CD003410.pub4"},{"key":"4814_CR17","volume-title":"Statistical method in biological assay","author":"DJ Finney","year":"1964","unstructured":"Finney DJ (1964) Statistical method in biological assay, 2nd edn. Charles Griffin & Co. Ltd, London","edition":"2"},{"issue":"1","key":"4814_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/00008877-199302000-00001","volume":"4","author":"RR Griffiths","year":"1993","unstructured":"Griffiths RR, Troisi JR, Silverman K, Mumford GK (1993) Multiple-choice procedure: an efficient approach for investigating drug reinforcement in humans. Behav Pharmacol 4(1):3\u201313","journal-title":"Behav Pharmacol"},{"key":"4814_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1192\/bjp.bp.106.026112","volume":"191","author":"C Haasen","year":"2007","unstructured":"Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D (2007) Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br J Psychiatry 191:55\u201362","journal-title":"Br J Psychiatry"},{"issue":"1","key":"4814_CR20","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.2105\/AJPH.2012.300874","volume":"103","author":"JR Havens","year":"2013","unstructured":"Havens JR, Lofwall MR, Frost SD, Oser CB, Leukefeld CG, Crosby RA (2013) Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. Am J Public Health 103(1):e44\u2013e52. https:\/\/doi.org\/10.2105\/AJPH.2012.300874","journal-title":"Am J Public Health"},{"issue":"2","key":"4814_CR21","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0022-3565(25)22236-4","volume":"250","author":"SJ Heishman","year":"1989","unstructured":"Heishman SJ, Stitzer ML, Bigelow GE, Liebson IA (1989) Acute opioid physical dependence in humans: effect of varying the morphine-naloxone interval. I. Pharmacol Exp Ther 250(2):485\u2013491","journal-title":"Pharmacol Exp Ther"},{"issue":"2","key":"4814_CR22","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/0091-3057(90)90421-D","volume":"36","author":"SJ Heishman","year":"1990","unstructured":"Heishman SJ, Stitzer ML, Bigelow GE, Liebson IA (1990) Acute opioid physical dependence in humans: effect of naloxone at 6 and 24 hours postmorphine. Pharmacol Biochem Behav 36(2):393\u2013399. https:\/\/doi.org\/10.1016\/0091-3057(90)90421-D","journal-title":"Pharmacol Biochem Behav"},{"issue":"3","key":"4814_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.drugalcdep.2010.06.009","volume":"112","author":"A Karow","year":"2010","unstructured":"Karow A, Reimer J, Schafer I, Krausz M, Haasen C, Verthein U (2010) Quality of life under maintenance treatment with heroin versus methadone in patients with opioid dependence. Drug Alcohol Depend 112(3):209\u2013215. https:\/\/doi.org\/10.1016\/j.drugalcdep.2010.06.009","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"4814_CR24","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0022-3565(25)23151-2","volume":"255","author":"KC Kirby","year":"1990","unstructured":"Kirby KC, Stitzer ML, Heishman SJ (1990) Acute opioid physical dependence in humans: effect of varying the morphine-naloxone interval II. J Pharmacol Exp Ther 255(2):730\u2013737","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 11","key":"4814_CR25","first-page":"S276","volume":"17","author":"BR Overholser","year":"2011","unstructured":"Overholser BR, Foster DR (2011) Opioid pharmacokinetic drug-drug interactions. Am J Manag Care 17(Suppl 11):S276\u2013S287","journal-title":"Am J Manag Care"},{"issue":"8","key":"4814_CR26","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa0810635","volume":"361","author":"E Oviedo-Joekes","year":"2009","unstructured":"Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, Schechter MT (2009) Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med 361(8):777\u2013786. https:\/\/doi.org\/10.1056\/NEJMoa0810635","journal-title":"N Engl J Med"},{"issue":"4","key":"4814_CR27","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jsat.2010.03.003","volume":"38","author":"E Oviedo-Joekes","year":"2010","unstructured":"Oviedo-Joekes E, Guh D, Brissette S, Marsh DC, Nosyk B, Krausz M, Anis A, Schechter MT (2010) Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: a pilot study. J Subst Abus Treat 38(4):408\u2013411. https:\/\/doi.org\/10.1016\/j.jsat.2010.03.003","journal-title":"J Subst Abus Treat"},{"issue":"5","key":"4814_CR28","doi-asserted-by":"publisher","first-page":"371","DOI":"10.5055\/jom.2011.0078","volume":"7","author":"E Oviedo-Joekes","year":"2011","unstructured":"Oviedo-Joekes E, Marsh DC, Guh D, Brissette S, Schechter MT (2011) Potency ratio of hydromorphone and diacetylmorphine in substitution treatment for long-term opioid dependency. J Opioid Manag 7(5):371\u2013376","journal-title":"J Opioid Manag"},{"issue":"5","key":"4814_CR29","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1001\/jamapsychiatry.2016.0109","volume":"73","author":"E Oviedo-Joekes","year":"2016","unstructured":"Oviedo-Joekes E, Guh D, Brissette S, Marchand K, MacDonald S, Lock K, Harrison S, Janmohamed A, Anis AH, Krausz M, Marsh DC, Schechter MT (2016) Hydromorphone compared with diacetylmorphine for long-term opioid dependence: a randomized clinical trial. JAMA Psychiatry 73(5):447\u2013455. https:\/\/doi.org\/10.1001\/jamapsychiatry.2016.0109","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"4814_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/bod.2510090207","volume":"9","author":"P Parab","year":"1988","unstructured":"Parab P, Ritschel W, Coyle D, Gregg R, Denson D (1988) Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects. Biopharm Drug Dispos 9(2):187\u2013199. https:\/\/doi.org\/10.1002\/bod.2510090207","journal-title":"Biopharm Drug Dispos"},{"issue":"4","key":"4814_CR31","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/jat\/30.4.267","volume":"30","author":"S Paterson","year":"2006","unstructured":"Paterson S, Cordero R (2006) Comparison of the various opiate alkaloid contaminants and their metabolites found in illicit heroin with 6-monoacetyl morphine as indicators of heroin ingestion. J Anal Toxicol 30(4):267\u2013273. https:\/\/doi.org\/10.1093\/jat\/30.4.267","journal-title":"J Anal Toxicol"},{"issue":"12","key":"4814_CR32","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1111\/j.1360-0443.2005.01225.x","volume":"100","author":"S Paterson","year":"2005","unstructured":"Paterson S, Lintzeris N, Mitchell TB, Cordero R, Nestor L, Strang J (2005) Validation of techniques to detect illicit heroin use in patients prescribed pharmaceutical heroin for the management of opioid dependence. Addiction 100(12):1832\u20131839. https:\/\/doi.org\/10.1111\/j.1360-0443.2005.01225.x","journal-title":"Addiction"},{"issue":"7150","key":"4814_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/bmj.317.7150.13","volume":"317","author":"TV Perneger","year":"1998","unstructured":"Perneger TV, Giner F, del Rio M, Mino A (1998) Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ 317(7150):13\u201318. https:\/\/doi.org\/10.1136\/bmj.317.7150.13","journal-title":"BMJ"},{"issue":"1","key":"4814_CR34","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0022-3565(25)22710-0","volume":"271","author":"KL Preston","year":"1994","unstructured":"Preston KL, Bigelow GE (1994) Drug discrimination assessment of agonist-antagonist opioids in humans: a three-choice saline-hydromorphone-butorphanol procedure. J Pharmacol Exp Ther 271(1):48\u201360","journal-title":"J Pharmacol Exp Ther"},{"key":"4814_CR35","first-page":"521","volume-title":"Goodman and Gilman\u2019s: the pharmacological basis of therapeutics","author":"T Reisine","year":"1996","unstructured":"Reisine T, Pasternak GW (1996) Opioid agonists and antagonists. In: Hardman JG, Limbird LE (eds) Goodman and Gilman\u2019s: the pharmacological basis of therapeutics. McGraw-Hill, New York, pp 521\u2013556"},{"issue":"1","key":"4814_CR36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2174\/157488406775268219","volume":"1","author":"EJ Rook","year":"2006","unstructured":"Rook EJ, Huitema AD, JMv R, Beijnen JH (2006) Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature. Curr Clin Pharmacol 1(1):109\u2013118. https:\/\/doi.org\/10.2174\/157488406775268219","journal-title":"Curr Clin Pharmacol"},{"issue":"39","key":"4814_CR37","first-page":"849","volume":"63","author":"RA Rudd","year":"2014","unstructured":"Rudd RA, Paulozzi LJ, Bauer MJ, Burleson RW, Carlson RE, Dao D, Davis JW, Dudek J, Eichler BA, Fernandes JC, Fondario A, Gabella B, Hume B, Huntamer T, Kariisa M, Largo TW, Miles J, Newmyer A, Nitcheva D, Perez BE, Proescholdbell SK, Sabel JC, Skiba J, Slavova S, Stone K, Tharp JM, Wendling T, Wright D, Zehner AM (2014) Increases in heroin overdose deaths \u2013 28 states, 2010 to 2012. MMWR Morb Mortal Wkly Rep 63(39):849\u2013854. DOI: mm6339a1 [pii]","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"4814_CR38","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1111\/j.1360-0443.2004.00834.x","volume":"99","author":"SC Sigmon","year":"2004","unstructured":"Sigmon SC, Wong CJ, Chausmer AL, Liebson IA, Bigelow GE (2004) Evaluation of an injection depot formulation of buprenorphine: placebo comparison. Addiction 99(11):1439\u20131449. https:\/\/doi.org\/10.1111\/j.1360-0443.2004.00834.x","journal-title":"Addiction"},{"issue":"3","key":"4814_CR39","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s002130000637","volume":"154","author":"KB Stoller","year":"2001","unstructured":"Stoller KB, Bigelow GE, Walsh SL, Strain EC (2001) Effects of buprenorphine\/naloxone in opioid-dependent humans. Psychopharmacology 154(3):230\u2013242. https:\/\/doi.org\/10.1007\/s002130000637","journal-title":"Psychopharmacology"},{"issue":"4","key":"4814_CR40","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s002130050066","volume":"148","author":"EC Strain","year":"2000","unstructured":"Strain EC, Stoller K, Walsh SL, Bigelow GE (2000) Effects of buprenorphine versus buprenorphine\/naloxone tablets in non-dependent opioid abusers. Psychopharmacology 148(4):374\u2013383. https:\/\/doi.org\/10.1007\/s002130050066","journal-title":"Psychopharmacology"},{"issue":"7","key":"4814_CR41","doi-asserted-by":"publisher","first-page":"556","DOI":"10.18553\/jmcp.2009.15.7.556","volume":"15","author":"SA Strassels","year":"2009","unstructured":"Strassels SA (2009) Economic burden of prescription opioid misuse and abuse. J Manag Care Pharm 15(7):556\u2013562. https:\/\/doi.org\/10.18553\/jmcp.2009.15.7.556","journal-title":"J Manag Care Pharm"},{"key":"4814_CR42","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Behavioral Health Statistics and Quality (2016) 2015 National Survey on Drug Use and Health: detailed tables"},{"issue":"1","key":"4814_CR43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/0304-3959(90)91102-O","volume":"41","author":"SL Wallenstein","year":"1990","unstructured":"Wallenstein SL, Houde RW, Portenoy R, Lapin J, Rogers A, Foley KM (1990) Clinical analgesic assay of repeated and single doses of heroin and hydromorphone. Pain 41(1):5\u201313. https:\/\/doi.org\/10.1016\/0304-3959(90)91102-O","journal-title":"Pain"},{"issue":"5","key":"4814_CR44","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/clpt.1994.71","volume":"55","author":"SL Walsh","year":"1994","unstructured":"Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE (1994) Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 55(5):569\u2013580. https:\/\/doi.org\/10.1038\/clpt.1994.71","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"4814_CR45","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0022-3565(25)10510-7","volume":"274","author":"SL Walsh","year":"1995","unstructured":"Walsh SL, Preston KL, Bigelow GE, Stitzer ML (1995) Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 274(1):361\u2013372","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"4814_CR46","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.drugalcdep.2008.05.007","volume":"98","author":"SL Walsh","year":"2008","unstructured":"Walsh SL, Nuzzo PA, Lofwall MR, Holtman JR Jr (2008) The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend 98(3):191\u2013202. https:\/\/doi.org\/10.1016\/j.drugalcdep.2008.05.007","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"4814_CR47","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2133\/dmpk.DMPK-13-RV-032","volume":"29","author":"Z Zahari","year":"2014","unstructured":"Zahari Z, Ismail R (2014) Influence of cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) polymorphisms on pain sensitivity and clinical response to weak opioid analgesics. Drug Metab Pharmacokinet 29(1):29\u201343. https:\/\/doi.org\/10.2133\/dmpk.DMPK-13-RV-032","journal-title":"Drug Metab Pharmacokinet"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-017-4814-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-017-4814-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-017-4814-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T03:38:49Z","timestamp":1751168329000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-017-4814-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,21]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["4814"],"URL":"https:\/\/doi.org\/10.1007\/s00213-017-4814-3","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"type":"print","value":"0033-3158"},{"type":"electronic","value":"1432-2072"}],"subject":[],"published":{"date-parts":[[2017,12,21]]},"assertion":[{"value":"15 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}